Atlas Trials

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

Clinical trial NCT02992132 · TERMINATED

Trial details

NCT number
NCT02992132
Sponsor
ACADIA Pharmaceuticals Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Agitation and Aggression in Alzheimer's Disease
Start date
2016-11-01
Primary completion
2018-01-25
Enrollment
111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.